BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 23616495)

  • 1. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
    Durante-Mangoni E; Signoriello G; Andini R; Mattei A; De Cristoforo M; Murino P; Bassetti M; Malacarne P; Petrosillo N; Galdieri N; Mocavero P; Corcione A; Viscoli C; Zarrilli R; Gallo C; Utili R
    Clin Infect Dis; 2013 Aug; 57(3):349-58. PubMed ID: 23616495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.
    Motaouakkil S; Charra B; Hachimi A; Nejmi H; Benslama A; Elmdaghri N; Belabbes H; Benbachir M
    J Infect; 2006 Oct; 53(4):274-8. PubMed ID: 16442632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.
    Bassetti M; Repetto E; Righi E; Boni S; Diverio M; Molinari MP; Mussap M; Artioli S; Ansaldi F; Durando P; Orengo G; Bobbio Pallavicini F; Viscoli C
    J Antimicrob Chemother; 2008 Feb; 61(2):417-20. PubMed ID: 18174197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M; Pujol M; Tubau F; Peña C; Montero A; Domínguez MA; Gudiol F; Ariza J
    J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin.
    Pantopoulou A; Giamarellos-Bourboulis EJ; Raftogannis M; Tsaganos T; Dontas I; Koutoukas P; Baziaka F; Giamarellou H; Perrea D
    Int J Antimicrob Agents; 2007 Jan; 29(1):51-5. PubMed ID: 17189095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
    Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
    Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Song JY; Lee J; Heo JY; Noh JY; Kim WJ; Cheong HJ; Hwang IS
    Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.
    Petrosillo N; Chinello P; Proietti MF; Cecchini L; Masala M; Franchi C; Venditti M; Esposito S; Nicastri E
    Clin Microbiol Infect; 2005 Aug; 11(8):682-3. PubMed ID: 16008625
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Borraz C; Gudiol F
    J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
    Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
    Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients.
    Trottier V; Namias N; Pust DG; Nuwayhid Z; Manning R; Marttos AC; Dunham MB; Schulman CI; McKenney MG
    Surg Infect (Larchmt); 2007 Aug; 8(4):437-43. PubMed ID: 17883360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan.
    Lin CC; Liu TC; Kuo CF; Liu CP; Lee CM
    J Microbiol Immunol Infect; 2010 Aug; 43(4):323-31. PubMed ID: 20688293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections.
    Durante-Mangoni E; Andini R; Signoriello S; Cavezza G; Murino P; Buono S; De Cristofaro M; Taglialatela C; Bassetti M; Malacarne P; Petrosillo N; Corcione A; Viscoli C; Utili R; Gallo C
    Clin Microbiol Infect; 2016 Dec; 22(12):984-989. PubMed ID: 27545697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nosocomial pneumonia caused by multiresistant Acinetobacter baumanii treated by colistin and rifampicin].
    Motaouakkil S; Charra B; Hachimi A; Benslama A
    Ann Fr Anesth Reanim; 2006 May; 25(5):543-4. PubMed ID: 16488103
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients.
    Tsioutis C; Kritsotakis EI; Karageorgos SA; Stratakou S; Psarologakis C; Kokkini S; Gikas A
    Int J Antimicrob Agents; 2016 Nov; 48(5):492-497. PubMed ID: 27542315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options for Acinetobacter baumannii infections.
    Vila J; Pachón J
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report.
    Biancofiore G; Tascini C; Bisà M; Gemignani G; Bindi ML; Leonildi A; Giannotti G; Menichetti F
    Minerva Anestesiol; 2007 Mar; 73(3):181-5. PubMed ID: 17159765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.